My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
July/August 2015
21st Century Cures Act Progresses Through Congress
The U.S. House of Representatives passed the 21st Century Cures Act, H.R. 6, last month with an overwhelming bipartisan vote of 344-77.  This legislation includes key IDSA priorities, such as the Limited Population Antibacterial Drug (LPAD) approval mechanism, a provision to improve the process for updating antimicrobial susceptibility breakpoints, increased funding for the National Institutes of Health (NIH), and an increase to the annual limit for the NIH loan repayment program.  Over the last few years, IDSA members have undertaken significant advocacy—through emails, phone calls and in person meetings with congressional staff and members of Congress—in support of these policies, and these efforts have been critical to the Society’s success in advancing these priorities.

The U.S. Senate is developing its own legislation—Innovations for Healthier Americans—that will be similar in scope to Cures.  IDSA is now advocating for inclusion of our priorities in this bill.

As part of these efforts, IDSA Antimicrobial Resistance Committee member, Helen Boucher, MD, FIDSA, spoke at a July 28 Senate briefing in support of the Senate LPAD legislation (the Promise for Antibiotics and Therapeutics for Health, or PATH Act, S. 185). She was joined by Janet Woodcock, MD, of the Food and Drug Administration (FDA), Prabha Fernandes of Cempra, and Alan Coukell of The Pew Charitable Trusts. The briefing garnered over 70 attendees, including key Senate staff and representatives from other stakeholder organizations.

You can help us advance the PATH Act by taking a minute or two to email your Senators through this link.

< Previous Article | Next Article >

Post a comment

Your name:

Your comment:

Guideline on Diagnosis and Management of Vertebral Osteomyelitits Released
CDC Updated Guidelines on Treatment of Sexually Transmitted Diseases
FDA Approves Technivie in Combination with Ribavirin for Treatment of HCV
CMS Issues FAQ Document on ICD-10 Implementation
White House Releases Five-Year HIV/AIDS Strategy
21st Century Cures Act Progresses Through Congress
House, Senate Committees Recommend 2016 Funding to Address Antibiotic Resistance
News from CDC: Recognizing the 20th Anniversary of the Emerging Infections Program
NIH Requests Input on its Strategic Plan
IDSA Comments on Criteria for $20 Million CARB Diagnostics Challenge
FDA Proposal Would Yield Better Data on Antibiotics in Meat, Poultry
Science Speaks Covers 8th International AIDS Conference
What Not to Miss at IDWeek 2015
OFID Offers Special Peer Review Track for Fellows of IDSA (FIDSA)
Latest OFID Podcast Features Martin Blaser on the Microbiome
FIDSA Designees Announced: 113 Distinguished Physicians, Scientists Honored
Members on the Move
Member Report
From the President
Setting IDSA’s Course to Lead the Future of ID
IDSA Compensation Survey: Take 5 Minutes to Help Us Advocate for You
Take Part in IDSA’s Future: Cast Your Vote in Board Elections
Journal Club
IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add '' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.